Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer (SCLC)
This project proposes to use bronchoscopic intratumoral chemotherapy for small cell lung cancer in two fashions: 1. to implement a prospective clinical trial to test the feasibility and efficacy of intralesional chemotherapy as consolidative therapy immediately following standard systemic chemotherapy and radiation therapy for patients with limited stage SCLC by comparing tumor growth and survival rates of the treatment group and compare the outcomes to historical controls 2. to implement a prospective clinical trial to test the feasibility and efficacy as measured by tumor growth and survival rates of intralesional chemotherapy for patients with recurrent SCLC after standard treatment.
Checked against the public recordLast updated Jun 11, 2015 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 3
- Sponsor
- University of Florida
- Interventions being studied
- Drug: Cisplatin
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: Competent adult English speaking subjects * With limited stage SCLC who have completed standard of care treatment who are responders with no evidence of disseminated disease other than CNS metastasis, * With recurrent disseminated SCLC after standard of care treatment with symptoms related to central tumor obstruction, * With recurrent limited stage SCLC with mediastinal/hilar recurrence not previously treated with intratumoral cisplatin Exclusion Criteria: * Subjects who do not meet the inclusion criteria * Subjects who, in the opinion of the investigator, are at risk undergoing a bronchoscopy
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of FloridaGainesville, Florida
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 11, 2015. Always confirm current availability with the study team.